In Q3 of fiscal 2026, the quarter ended Feb 28, 2026, Cannabis Bioscience International Holdings, Inc. reported revenue of $11,205, down 25.0% from the same quarter a year earlier. It recorded a net loss of $103,933. The operating loss came to $93,259, an operating margin of -832.3%. Diluted earnings per share were -$0.00.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Feb 28, 2026
|
Q3 FY2026
Feb 28, 2026
|
Q2 FY2026
Nov 30, 2025
|
Q1 FY2026
Aug 31, 2025
|
Q4 FY2025
May 31, 2025
|
Q3 FY2025
Feb 28, 2025
|
Q1 FY2025
Aug 31, 2024
|
Q4 FY2024
May 31, 2024
|
Q3 FY2024
Feb 29, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
0
-64.1%
|
0
-25.0%
|
0
|
0
-86.5%
|
0
-53.9%
|
0
-59.0%
|
0
|
0
|
0
|
| Cost of revenue |
0
-42.3%
|
0
-84.3%
|
0
|
0
-2.6%
|
0
-54.0%
|
0
+64.2%
|
0
|
0
|
0
|
| Gross profit |
0
-67.4%
|
0
+282.8%
|
0
|
0
-90.6%
|
0
-53.9%
|
-0
-118.1%
|
0
|
0
|
0
|
| Selling, general and administrative |
0
-80.5%
|
0
-46.5%
|
0
|
0
-62.0%
|
-0
-609.8%
|
0
+98.4%
|
0
|
0
|
0
|
| Operating income |
-0
-26.2%
|
-0
+27.8%
|
-0
|
-0
+23.4%
|
-0
-355.2%
|
-0
+19.2%
|
-0
|
-0
|
-0
|
| Net income |
-1
-8.9%
|
-0
+42.7%
|
-0
|
-0
-8.3%
|
-0
-55.8%
|
-0
+13.4%
|
-0
|
-0
|
-0
|
| Basic EPS |
-0.00
+0.5%
|
-0.00
+47.1%
|
-0.00
|
-0.00
+0.0%
|
-0.00
-44.3%
|
-0.00
+15.0%
|
-0.00
|
-0.00
|
-0.00
|
| Diluted EPS |
-0.00
+0.5%
|
-0.00
+47.1%
|
-0.00
|
-0.00
+0.0%
|
-0.00
-44.3%
|
-0.00
+15.0%
|
-0.00
|
-0.00
|
-0.00
|
| Weighted average shares, basic |
11,503
+9.5%
|
11,627
+8.4%
|
11,627
|
11,627
+11.2%
|
11,137
+7.9%
|
10,726
+3.4%
|
10,459
|
10,318
|
10,372
|
| Weighted average shares, diluted |
11,503
+9.5%
|
11,627
+8.4%
|
11,627
|
11,627
+11.2%
|
11,137
+7.9%
|
10,726
+3.4%
|
10,459
|
10,318
|
10,372
|
| Other measures | |||||||||
| Interest coverage |
-2.68x
|
-8.65x
|
-5.37x
|
-4.31x
|
-1.31x
|
-5.75x
|
-41.73x
|
—
|
—
|
| Margins | |||||||||
| Gross margin |
78.78%
|
72.82%
|
80.29%
|
66.35%
|
87.00%
|
-29.90%
|
95.33%
|
86.98%
|
67.57%
|
| Operating margin |
-322.60%
|
-832.30%
|
-180.00%
|
-309.02%
|
-385.91%
|
-865.54%
|
-54.56%
|
-39.06%
|
-439.35%
|
| Profit margin |
-416.81%
|
-927.56%
|
-219.59%
|
-341.51%
|
-605.74%
|
-1,213.87%
|
-42.66%
|
-179.19%
|
-574.53%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- CBIH (OTC)
- Fiscal year ends
- May 31
- Incorporated in
- CO
- Headquarters
- Yantis, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1411057
- Former names
- CHINA INFRASTRUCTURE CONSTRUCTION Corp (until Aug 24, 2022); FIDELITY AVIATION CORP (until Sep 15, 2009)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.